+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
KRAS Inhibitor Market by Indication, Mechanism of Action, Mutation Type, Dosage Form, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
KRAS Inhibitor Market by Indication, Mechanism of Action, Mutation Type, Dosage Form, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
New

KRAS Inhibitor Market by Indication, Mechanism of Action, Mutation Type, Dosage Form, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6125434
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The resurgence of interest in KRAS inhibitors marks a pivotal moment in oncology research, reflecting decades of scientific pursuit to target what was once deemed an undruggable protein. Recent breakthroughs in structural biology and medicinal chemistry have illuminated hidden pockets on mutant KRAS isoforms, allowing innovators to craft molecules with unprecedented specificity and potency. At the same time, a deeper understanding of downstream signaling pathways has opened avenues for synergistic combinations that may overcome adaptive resistance.

In parallel, advancements in diagnostic technologies-ranging from liquid biopsies to next-generation sequencing-are enabling real-time patient stratification, ensuring that therapies precisely match individual mutational profiles. These developments underscore the critical shift toward personalized medicine in oncology, where therapeutic decisions hinge on the genetic blueprint of each tumor.

This executive summary distills the most influential trends shaping the KRAS inhibitor landscape, providing leaders with actionable intelligence. By weaving together clinical progress, regulatory milestones, and commercial strategies, it equips stakeholders with the perspective needed to navigate the complexities of a market poised for transformative growth.

Unveiling the Paradigm-Altering Transformations Shaping KRAS Inhibitor Innovation and Clinical Impact in Oncological Therapeutics Worldwide

Over the past two years, the KRAS inhibitor landscape has undergone a comprehensive metamorphosis, driven by pioneering therapies that challenge long-held assumptions in drug discovery. Next-generation covalent inhibitors targeting G12C mutations are now complemented by allosteric and non-covalent compounds designed to engage a broader spectrum of oncogenic KRAS variants. These innovations not only diversify the therapeutic toolkit but also promise enhanced safety profiles and resistance management.

Simultaneously, the integration of KRAS inhibitors with checkpoint inhibitors and kinase inhibitors has sparked a wave of combination trials. Early data suggest that concurrent signaling blockade can unlock deeper and more durable tumor regressions, particularly in refractory disease settings. Regulatory bodies, responding to unmet needs in colorectal, lung, and pancreatic cancers, have introduced accelerated approval pathways that compress timelines from IND submission to market entry, incentivizing rapid iteration in R&D.

As capital flows into biotech ventures and established pharmaceutical players alike, the competitive dynamic is intensifying. Strategic collaborations between diagnostics companies and drug developers are forging comprehensive precision oncology platforms, enabling real-time response monitoring and adaptive trial designs. These shifts collectively signal the dawn of a new era in KRAS inhibition-one defined by agility, personalization, and multidimensional therapeutic strategies.

Assessing the Strategic Supply Chain Adaptations and Cost Dynamics Resulting from United States Tariff Revisions in 2025

The implementation of renewed import tariffs in the United States in 2025 has introduced significant complexities across the pharmaceutical supply chain, particularly impacting KRAS inhibitor development and distribution. Raw materials for small molecule synthesis, often sourced internationally, now carry elevated costs that reverberate through contract research organizations, manufacturing partners, and ultimately end users.

In response, companies have accelerated localization of key production stages, forging domestic partnerships for API synthesis and formulation. This strategic pivot not only mitigates tariff exposure but also strengthens supply chain resilience in the face of geopolitical volatility. Moreover, parallel efforts to qualify alternate suppliers and validate dual-source manufacturing facilities have become integral to ensuring uninterrupted clinical trial supply and commercial launch readiness.

While cost pressures persist, the industry’s proactive measures have yielded new collaborative models with contract development and manufacturing organizations, emphasizing co-investment in capacity expansion. These alliances underscore a broader trend toward vertical integration, positioning stakeholders to absorb tariff fluctuations while maintaining the momentum of KRAS inhibitor innovation.

Deriving Comprehensive Insights from Multi-Dimensional Segmentation Based on Indication Mechanism Mutation Dosage End User and Distribution Channels

A granular examination by indication reveals distinct trajectories for colorectal cancer, non-small cell lung cancer, and pancreatic cancer, each presenting unique opportunities for therapeutic differentiation. In colorectal settings, second-line therapies are exploring novel combination regimens, while lung oncology continues to benefit from rapid patient identification through scalable screening. Pancreatic applications, historically challenged by dense stroma, now leverage specialized delivery technologies to enhance target engagement.

Mechanism-based segmentation highlights the rise of allosteric inhibitors that exploit transient switch II pocket conformations, alongside covalent compounds that irreversibly bind GDP-loaded mutants. At the same time, emerging non-covalent agents seek to deliver broader mutant selectivity with reduced off-target liabilities. The convergence of these modalities reflects a strategic push to transcend single-mutation focus and address a wider mutational spectrum.

When considering mutation type, the G12C cohort remains the most clinically advanced, yet G12D and G12V programs are accelerating through early-phase pipelines, bolstered by in vivo efficacy data. Dosage form differentiation further influences market dynamics, with injectable solutions offering rapid dose adjustments in acute care settings and oral tablets driving outpatient adoption and patient convenience.

Across the healthcare continuum, cancer care centers and specialty clinics are emerging as high-intensity adoption hubs, supported by hospital pharmacies equipped for complex infusion protocols. Meanwhile, retail and specialty pharmacies play an increasingly important role in oral treatment distribution, complemented by the rise of online pharmacy channels that facilitate home delivery and adherence monitoring.

Illuminating Key Regional Dynamics Shaping KRAS Inhibitor Adoption Across the Americas EMEA and Asia-Pacific Territories

In the Americas, robust R&D funding and streamlined regulatory frameworks have fostered rapid clinical development of KRAS inhibitors, particularly in regions with established biotech hubs. Patient access schemes and real-world evidence collaborations are proving instrumental in shaping reimbursement pathways and accelerating formulary placements.

Within Europe, the Middle East, and Africa, the regulatory mosaic presents both challenges and opportunities. Harmonization efforts across the EU have reduced approval fragmentation, yet variable healthcare budgets persist. In EMEA, strategic partnerships with regional oncology networks are enabling early launch acceleration, while funding initiatives in certain Gulf Cooperation Council countries are driving adoption in specialized cancer institutes.

Asia-Pacific markets exhibit strikingly diverse dynamics; mature markets like Japan and South Korea benefit from advanced genetic screening infrastructure and supportive government policies, whereas emerging economies in Southeast Asia are navigating infrastructural constraints. In this region, local manufacturing incentives and tailored licensing agreements are critical to scaling patient access and embedding KRAS inhibitors within national oncology programs.

Revealing the Strategic Moves and Collaborative Partnerships Driving Leadership in KRAS Inhibitor Innovation

Several leading organizations have distinguished themselves through targeted pipeline investments, strategic collaborations, and adaptive commercialization strategies. One global pharmaceutical company has accelerated its G12C program through a series of precision engineering iterations, while forging partnerships with diagnostic firms to co-develop companion assays.

A prominent biotech innovator has expanded its footprint by acquiring complementary small molecule expertise, enhancing its capacity to address non-G12C mutations. This move underscores a broader consolidation trend aimed at unifying discovery platforms and streamlining clinical operations. Other entities are forging alliances with contract manufacturers to secure flexible API and formulation capacity, ensuring swift scale-up post-approval.

Furthermore, cross-sector collaborations between drug developers and academic consortia have catalyzed early access initiatives, particularly in underserved indications with high unmet need. Such alliances are facilitating adaptive trial designs that rapidly incorporate emerging biomarkers, ultimately refining patient selection and optimizing therapeutic outcomes.

Strategic Guidance for Industry Executives to Strengthen Portfolios Drive Diagnostic Integration and Bolster Supply Chain Resilience

Industry leaders must prioritize the diversification of their KRAS inhibitor portfolios by pursuing next-generation modalities that address a broader mutational landscape. By allocating resources to both allosteric and non-covalent chemotypes, organizations can create differentiated offerings that mitigate resistance risks.

In parallel, integrating companion diagnostic development into early clinical programs will be essential for seamless market entry and payor negotiations. Embedding real-time biomarker analysis within clinical trials not only enhances patient stratification but also generates compelling evidence for value-based contracting.

To navigate escalating supply chain complexities, executives should explore strategic co-investment models with contract manufacturers, securing dual sourcing for critical raw materials and leveraging capacity expansions to buffer tariff impacts. Establishing transparent supplier scorecards and agile procurement frameworks will further strengthen resilience.

Finally, fostering a culture of cross-functional collaboration-uniting R&D, medical affairs, commercial, and regulatory teams-will streamline go-to-market strategies. By harnessing integrated data platforms and advanced analytics, companies can anticipate market shifts and tailor engagement tactics to evolving stakeholder expectations.

Detailing the Robust Mixed-Method Framework Employing Expert Interviews Secondary Analysis and Scenario Mapping

This study employed a mixed-method research framework that blended qualitative expert interviews with comprehensive secondary data analysis. Primary insights were garnered through discussions with leading oncologists, pharmacologists, and supply chain strategists, providing nuanced perspectives on clinical progress and logistical adaptations.

Concurrently, peer-reviewed journals, clinical trial registries, regulatory announcements, and patent filings were systematically reviewed to ensure accuracy and currency. Data triangulation techniques validated emerging themes across multiple sources, enhancing the reliability of strategic conclusions. Market intelligence was further enriched by examining corporate filings, investor presentations, and scientific conference proceedings.

Analytical methods included thematic coding for qualitative inputs and scenario mapping to explore potential outcomes under different regulatory and commercial contingencies. Findings were synthesized into strategic frameworks, enabling clear delineation of disruptive factors and actionable recommendations for stakeholders.

Synthesis of Critical Findings and Strategic Imperatives for Sustained Leadership in the Evolving KRAS Inhibitor Domain

The convergence of scientific ingenuity, regulatory agility, and strategic partnerships has propelled KRAS inhibitors to the forefront of precision oncology. Advances in structural targeting, combined with sophisticated diagnostic profiling, have transformed once elusive oncogenic drivers into tractable therapeutic targets. Meanwhile, evolving supply chain strategies and regional market adaptations underscore the industry’s resilience amid geopolitical and economic headwinds.

As the competitive landscape intensifies, the ability to integrate real-world evidence, optimize combination regimens, and navigate complex regulatory terrains will define market leaders. Organizations that balance robust R&D pipelines with strategic co-development partnerships will be best positioned to deliver enduring patient benefit and sustainable growth.

Ultimately, this report illuminates the pathways through which stakeholders can harness emerging opportunities, mitigate risks, and chart a confident course in the rapidly evolving KRAS inhibitor domain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Colorectal Cancer
    • Non-Small Cell Lung Cancer
    • Pancreatic Cancer
  • Mechanism Of Action
    • Allosteric Inhibitors
    • Covalent Inhibitors
    • Non-Covalent Inhibitors
  • Mutation Type
    • G12C
    • G12D
    • G12V
  • Dosage Form
    • Injectable Solutions
    • Oral Tablets
  • End User
    • Cancer Care Centers
    • Hospitals
    • Retail Pharmacies
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Amgen Inc.
  • Mirati Therapeutics, Inc.
  • Revolution Medicines, Inc.
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc.
  • Carmot Therapeutics, Inc.
  • Hua Medicine Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of next-generation covalent KRAS G12C inhibitors with improved selectivity and potency
5.2. Adoption of combination regimens pairing KRAS inhibitors with immune checkpoint blockade in solid tumors
5.3. Advancements in precision diagnostics for identifying KRAS mutation subtypes and treatment response biomarkers
5.4. Growing investment in pan-KRAS inhibitors targeting multiple KRAS mutations beyond G12C in clinical pipelines
5.5. Increasing focus on overcoming KRAS inhibitor resistance through novel allosteric binding strategies and combination approaches
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. KRAS Inhibitor Market, by Indication
8.1. Introduction
8.2. Colorectal Cancer
8.3. Non-Small Cell Lung Cancer
8.4. Pancreatic Cancer
9. KRAS Inhibitor Market, by Mechanism of Action
9.1. Introduction
9.2. Allosteric Inhibitors
9.3. Covalent Inhibitors
9.4. Non-Covalent Inhibitors
10. KRAS Inhibitor Market, by Mutation Type
10.1. Introduction
10.2. G12C
10.3. G12D
10.4. G12V
11. KRAS Inhibitor Market, by Dosage Form
11.1. Introduction
11.2. Injectable Solutions
11.3. Oral Tablets
12. KRAS Inhibitor Market, by End User
12.1. Introduction
12.2. Cancer Care Centers
12.3. Hospitals
12.4. Retail Pharmacies
12.5. Specialty Clinics
13. KRAS Inhibitor Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
13.5. Specialty Pharmacy
14. Americas KRAS Inhibitor Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa KRAS Inhibitor Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific KRAS Inhibitor Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Mirati Therapeutics, Inc.
17.3.3. Revolution Medicines, Inc.
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Janssen Pharmaceuticals, Inc.
17.3.6. Carmot Therapeutics, Inc.
17.3.7. Hua Medicine Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. KRAS INHIBITOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. KRAS INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. KRAS INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. KRAS INHIBITOR MARKET: RESEARCHAI
FIGURE 28. KRAS INHIBITOR MARKET: RESEARCHSTATISTICS
FIGURE 29. KRAS INHIBITOR MARKET: RESEARCHCONTACTS
FIGURE 30. KRAS INHIBITOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. KRAS INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 90. CANADA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 91. CANADA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 94. CANADA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 95. CANADA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. CANADA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. MEXICO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. MEXICO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. MEXICO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 106. MEXICO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 107. MEXICO KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. MEXICO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. GERMANY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 164. GERMANY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 165. GERMANY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. GERMANY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. GERMANY KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. GERMANY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. FRANCE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. FRANCE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. FRANCE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 180. FRANCE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 181. FRANCE KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. FRANCE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. ITALY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 200. ITALY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 201. ITALY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 202. ITALY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 203. ITALY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. ITALY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ITALY KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. ITALY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SPAIN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. SPAIN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. SPAIN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 216. SPAIN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 217. SPAIN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. SPAIN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. DENMARK KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. DENMARK KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. DENMARK KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 264. DENMARK KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 265. DENMARK KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. DENMARK KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. QATAR KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 284. QATAR KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 285. QATAR KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 286. QATAR KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 287. QATAR KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. QATAR KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. QATAR KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. QATAR KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. QATAR KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. QATAR KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. FINLAND KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. FINLAND KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. FINLAND KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 298. FINLAND KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 299. FINLAND KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 300. FINLAND KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 301. FINLAND KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FINLAND KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. FINLAND KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. FINLAND KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. EGYPT KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. EGYPT KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. EGYPT KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 332. EGYPT KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 333. EGYPT KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 334. EGYPT KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 335. EGYPT KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 336. EGYPT KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 337. EGYPT KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. EGYPT KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. EGYPT KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. EGYPT KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. TURKEY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. TURKEY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 343. TURKEY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 344. TURKEY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 345. TURKEY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 346. TURKEY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 347. TURKEY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 348. TURKEY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 349. TURKEY KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 350. TURKEY KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 351. TURKEY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 352. TURKEY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 353. ISRAEL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 354. ISRAEL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 355. ISRAEL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 356. ISRAEL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 357. ISRAEL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 358. ISRA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this KRAS Inhibitor market report include:
  • Amgen Inc.
  • Mirati Therapeutics, Inc.
  • Revolution Medicines, Inc.
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc.
  • Carmot Therapeutics, Inc.
  • Hua Medicine Co., Ltd.

Related Topics

Related Reports

KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030 - Product Image

KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

  • Report
  • 240 Pages
  • Global
From
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
TROP-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

TROP-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
CTLA-4 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

CTLA-4 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.